Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide

NCT00990652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: Bortezomib
DRUG: Temozolomide

Sponsor

Northwestern University

Collaborators

[object Object]